The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain
Abstract
It has been postulated that the G protein-coupled receptor, GPR55, is a third cannabinoid receptor. Given that the ligands at the CB(1) and CB(2) receptors are effective analgesic and anti-inflammatory agents, the role of GPR55 in hyperalgesia associated with inflammatory and neuropathic pain has been investigated. As there are no well-validated GPR55 tool compounds, a GPR55 knockout (GPR55(-/-)) mouse line was generated and fully backcrossed onto the C57BL/6 strain. General phenotypic analysis of GPR55(-/-) mice revealed no obvious primary differences, compared with wild-type (GPR55(+/+)) littermates. GPR55(-/-) mice were then tested in the models of adjuvant-induced inflammation and partial nerve ligation. Following intraplantar administration of Freund's complete adjuvant (FCA), inflammatory mechanical hyperalgesia was completely absent in GPR55(-/-) mice up to 14 days post-injection. Cytokine profiling experiments showed that at 14 days post-FCA injection there were increased levels of IL-4, IL-10, IFN gamma and GM-CSF in paws from the FCA-injected GPR55(-/-) mice when compared with the FCA-injected GPR55(+/+) mice. This suggests that GPR55 signalling can influence the regulation of certain cytokines and this may contribute to the lack of inflammatory mechanical hyperalgesia in the GPR55(-/-) mice. In the model of neuropathic hypersensitivity, GPR55(-/-) mice also failed to develop mechanical hyperalgesia up to 28 days post-ligation. These data clearly suggest that the manipulation of GPR55 may have therapeutic potential in the treatment of both inflammatory and neuropathic pain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Deletion of a putative novel cannabinoid receptor, GPR55, is also associated with the failure to develop mechanical hyperalgesia following partial sciatic nerve ligation.72”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [72]
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Seltzer, Z., Dubner, R., & Shir, Y. (1990) · Pain · doi:10.1016/0304-3959(90)91074-s · Cited by 1,847
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
A method for measurement of analgesic activity on inflamed tissue.
Randall, L. O., & Selitto, J. J. (1957) · PubMed · Cited by 1,568
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,526
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current
Lauckner, J. E., Jensen, J. B., Chen, H.-Y., Lu, H., Hille, B., & Mackie, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711278105 · Cited by 732
Pharmacological Actions of Cannabinoids
Pertwee, R. G. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_1 · Cited by 613
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors
Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J., Rubino, T., Michalski, C. W., Marsicano, G., Monory, K., et al. (2007) · Nature Neuroscience · doi:10.1038/nn1916 · Cited by 571
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T. I., Zimmer, A. M., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 546
Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug development?
Verri, W. A., Jr., Cunha, T. M., Parada, C. A., Poole, S., Cunha, F. Q., & Ferreira, S. H. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.001 · Cited by 538
Ibrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834309100 · Cited by 491
Identification of GPR55 as a lysophosphatidylinositol receptor
Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., & Sugiura, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.078 · Cited by 460
Brown, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707481 · Cited by 410
Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains
Markel, P. D., Shu, P., Ebeling, C., Carlson, G. A., Nagle, D. L., Smutko, J. S., & Moore, K. J. (1997) · Nature Genetics · doi:10.1038/ng1197-280 · Cited by 401
Evidence for novel cannabinoid receptors
Begg, M., Pacher, P., Bátkai, S., Osei‐Hyiaman, D., Offertáler, L., Mo, F.-M., LIU, J., & Kunos, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.005 · Cited by 396
Sawzdargo, M., Nguyen, T., Lee, D. K., Lynch, K. R., Cheng, R., Heng, H. H., George, S. R., & O’Dowd, B. F. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00277-0 · Cited by 378
In silico patent searching reveals a new cannabinoid receptor
Baker, D., Pryce, G., Davies, W. I. L., & Hiley, C. R. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.003 · Cited by 347
Núñez, E., Benito, C., Pazos, M. R., Barbáchano, A., Fajardo, O., González, S. R., Tolón, R. M., & Romero, J. (2004) · Synapse · doi:10.1002/syn.20050 · Cited by 346
Speed congenics: a classic technique in the fast lane (relatively speaking)
Wakeland, E. K., Morel, L. M., Achey, K., Yui, M. A., & Longmate, J. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01126-2 · Cited by 333
Cannabinoid Receptors and Endocannabinoids: Evidence for New Players
Mackie, K., & Stella, N. (2006) · The AAPS Journal · doi:10.1007/bf02854900 · Cited by 303
Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288
Johns, D. G., Behm, D. J., Walker, D. J., Zhang, A., Shapland, E. M., Daniels, D. A., Riddick, M., Dowell, S. J., Staton, P. C., Green, P., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707419 · Cited by 251
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
Clayton, N., Marshall, F. H., Bountra, C., & O'Shaughnessy, C. T. (2002) · Pain · doi:10.1016/s0304-3959(01)00454-7 · Cited by 247
Inhibition of Inflammatory Hyperalgesia by Activation of Peripheral CB2Cannabinoid Receptors
Quartilho, A., Mata, H. P., Ibrahim, M. M., Vanderah, T. W., Porreca, F., Makriyannis, A., & Malan, T. P. (2003) · Anesthesiology · doi:10.1097/00000542-200310000-00031 · Cited by 243
Selective Ligands and Cellular Effectors of a G Protein-Coupled Endothelial Cannabinoid Receptor
Offertáler, L., Mo, F.-M., Bátkai, S., Liu, J., Begg, M., Razdan, R. K., Martin, B. R., Bukoski, R. D., & Kunos, G. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.699 · Cited by 227
CB2 cannabinoid receptor mediation of antinociception
Ibrahim, M. M., Rude, M. L., Stagg, N. J., Mata, H. P., Lai, J. Y., Vanderah, T. W., Porreca, F., Buckley, N. E., Makriyannis, A., & Malan, P. T. (2006) · Pain · doi:10.1016/j.pain.2005.12.018 · Cited by 173
Vale, M. L., Marques, J. B., Moreira, C. A., Rocha, F. A. C., Ferreira, S. H., Poole, S., Cunha, F. Q., & Ribeiro, R. A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038703 · Cited by 152
Hohmann, A. G., Farthing, J. N., Zvonok, A. M., & Makriyannis, A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060079 · Cited by 124
Development of SHIRPA to characterise the phenotype of gene-targeted mice
Hatcher, J. P., Jones, D. N. C., Rogers, D. C., Hatcher, P. D., Reavill, C., Hagan, J. J., & Hunter, A. J. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00275-3 · Cited by 103
Elmes, S. J. R., Winyard, L. A., Medhurst, S. J., Clayton, N. M., Wilson, A. W., Kendall, D. A., & Chapman, V. (2005) · Pain · doi:10.1016/j.pain.2005.09.005 · Cited by 97
Whiteside, G. T., Gottshall, S. L., Boulet, J. M., Chaffer, S. M., Harrison, J., Pearson, M. S., Turchin, P. I., Mark, L., Garrison, A. E., & Valenzano, K. J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.10.043 · Cited by 94
Kleinschnitz, C., Brinkhoff, J., Zelenka, M., Sommer, C., & Stoll, G. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.12.013 · Cited by 90
Bradykinin B1 and B2 receptors, tumour necrosis factor α and inflammatory hyperalgesia
Poole, S., Lorenzetti, B. B., da Cunha, J. M., Cunha, F. Q., & Ferreira, S. H. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702347 · Cited by 85
Interferon-γ receptors in nociceptive pathways
Robertson, B., Xu, X., Hao, J., Wiesenfeld‐Hallin, Z., Mhlanga, J., Grant, G., & Kristensson, K. (1997) · Neuroreport · doi:10.1097/00001756-199703240-00050 · Cited by 84
Cannabinoid CB2 receptor agonist activity in the hindpaw incision
LaBuda, C. J., Koblish, M., & Little, P. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.10.020 · Cited by 76
Interleukin-10 reduces the endotoxin-induced hyperalgesia in mice
Kanaan, S. A., Poole, S., Saadé, N. E., Jabbur, S. J., & Safieh‐Garabedian, B. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00027-7 · Cited by 69
GPR55 as a New Cannabinoid Receptor: Still a Long Way to Prove It
Petitet, F., DONLAN, M. E., & Michel, A. G. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00370.x · Cited by 65
Therapeutic potential of cannabinoid receptor agonists as analgesic agents
Fox, A., & Bevan, S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.695 · Cited by 60
George, A., Kleinschnitz, C., Zelenka, M., Brinkhoff, J., Stoll, G., & Sommer, C. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.02.011 · Cited by 51
MacDonald, R. E., Bingham, S., Bond, B. C., Parsons, A. A., & Philpott, K. L. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(01)00086-9 · Cited by 47
Vikman, K. S., Siddall, P. J., & Duggan, A. W. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.059 · Cited by 38
CB2 cannabinoid receptor mediation of antinociception
Ibrahim, M. M., Rude, M. L., Stagg, N. J., Mata, H. P., Lai, J., Vanderah, T. W., Porreca, F., Buckley, N. E., Makriyannis, A., & Malan, T. P. (2006) · Acute Pain · doi:10.1016/j.acpain.2006.08.026 · Cited by 4
Cited by
Sorted by citations
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 889
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 440
Emerging roles of lysophospholipids in health and disease
Tan, S. T., Ramesh, T., Toh, X. R., & Nguyen, L. N. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101068 · Cited by 386
Metadata
- Authors
- Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., Fulleylove, M., Lancaster, H. C., Smith, J. C., Bailey, L. T., Wise, A., Brown, A. J., Richardson, J. C., & Chessell, I. P.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- King's College London (GB)
- Corresponding author
- Staton, Penny C.
- Venue
- Pain
- Published
- 2008-09-30
- Volume
- 139
- Issue
- 1
- Pages
- 225-236
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2015263236
- Cited by
- 270
- References
- 49
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 12 · 2022: 15 · 2021: 21 · 2020: 18 · 2019: 10 · 2018: 9 · 2017: 20 · 2016: 15 · 2015: 16 · 2014: 10 · 2013: 14 · 2012: 23
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pain (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- GPR55, cannabinoid receptors, mechanical hyperalgesia, inflammatory pain, neuropathic pain, adjuvant-induced inflammation, cytokine expression, analgesia
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Female, Hyperalgesia, Inflammation, Ligation, Male, Mice, Inbred C57BL, Molecular Sequence Data, Neuralgia, Pain Measurement, Physical Stimulation, Mice, Knockout, Inflammation Mediators, Receptors, Cannabinoid, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
